Press Release

Limited July 30, 2026 Ref:- GHL/2026-27/EXCH/35 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Code: 543654 Symbol: MEDANTA Sub: Press Release Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of the Press Release, for the first quarter ended June 30, 2026 Results. Kindly take the above on record. Thanking you, Yours faithfully For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035 Encl: a/a Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Press Release GLOBAL HEALTH LIMITED 30th July, 2026 Medanta continues on its growth trajectory; delivered yet again highest ever quarterly Total Income and EBITDA in Q1 FY27 o Consolidated Total Income at INR 13,262 million, up by 26.2% y-o-y o EBITDA ex Noida at INR 3,201 million, up 23.9% y-o-y with margins of 25.8% Gurugram, 30th July, 2026: Global Health Limited (NSE: Medanta, BSE: 543654), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its unaudited consolidated financial results for the quarter ending 30th June, 2026. Consolidated Results Snapshot: Q1 FY2027 Quarter INR million Q1FY2026 Q4FY2026 Q1FY2027 Y-o-Y Growth Financials Total income 10,513 11,958 13,262 26.2% EBITDA** 2,553 2,906 3,153 23.5% EBITDA Margins % 24.3% 24.3% 23.8% (51) bps Profit before tax* 2,081 1,873 2,133 2.5% Profit after tax 1,590 1,417 1,573 -1.1% Operational KPI Operational Beds (Census) 2,487 2,950 3,037 22.1% Occupancy 63.2% 60.9% 62.6% (53) bps ARPOB (INR) 66,584 66,687 70,244 5.5% ALOS (days) 3.03 3.06 2.87 -5.2% *Q1FY26 had a non-recurring exceptional income of INR 196 million primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHL **EBITDA represents EBITDA before ESOP Expenses Consolidated Highlights of the Quarter Ended 30th June, 2026 (Q1 FY2027)  Highest ever quarterly total income of INR 13,262 million; growth of 26.2% y-o-y  EBITDA (ex-Noida) grew 23.9 % y-o-y to INR 3,201 with improved margins of 25.8% in Q1 FY27. Reported EBITDA including Noida was INR 3,153 million, growth of 23.5% y-o-y and margins of 23.8%  Noida hospital generated Total Income of INR 855 million and EBITDA loss of INR 49 million in Q1 FY27, compared to total income of INR 525 million and EBITDA loss of INR 236 million reported in Q4 FY26  Profit After Tax was INR 1,573 million, compared to INR 1,590 million in Q1FY26. PAT margins were at 11.9% compared to 15.1% in Q1 FY26. To highlight, Q1FY26 had a non- recurring exceptional income of INR 196 million primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHL.  During the quarter, total 72 new beds were added across the network; 21 beds were added at Lucknow and 51 beds in Noida Press Release GLOBAL HEALTH LIMITED 30th July, 2026  Volume growth continues to remain robust, In-patient count increased by 27.7% while Out- patient count increased by 34.5% y-o-y  Occupied bed days increased by 21.1% y-o-y, representing an occupancy of ~63% on increased bed capacity while excluding Noida, occupancy stood at 66%.  ARPOB was INR 70,224, up by 5.5% y-o-y, driven by improvement in ALOS (from 3.03 days in Q1FY26 to 2.87 days in Q1FY27) and change in case mix  ARPP for the quarter was INR 201,891 compared to INR 201,795 in Q1FY26  During the quarter, International Patients Revenue increased by 23.0% y-o-y to INR 782 million  OPD Pharmacy (Hospital & Retail) business continues to witness robust growth. Revenue increased by 50.9% y-o-y to INR 609 million in Q1 FY27 Commenting on Q1 FY2027 results, Mr. Pankaj Sahni, Group CEO and Director said: “FY2027 started on a strong note with Q1FY2027 witnessing highest ever quarterly Total Income and EBITDA with year-on-year growth of 26.2% and 23.5%, respectively. This robust performance was driven by significant growth in patient volumes and improved realizations. While Patna and Lucknow continue to witness consistent growth on y-o-y basis, our Noida unit has started contributing in a meaningful manner on a quarterly basis. In line with our expectation, we have witnessed a significant decline in EBITDA losses at Noida for the quarter. During the quarter, we added 72 beds across Noida and Lucknow and expecting to operationalise our new 80 bed cancer facility in Indore in the next few months. On the projects front, we have scaled up our plans for Guwahati, which will now have a 650 bedded super specialty hospital. With this we would be adding 2,950 beds across five greenfield projects to be executed over the next few years. With a strong balance sheet and deep clinical expertise, we are committed to expanding our network through a disciplined, quality‑anchored approach that ensures sustainable growth for all our stakeholders.” Key Developments – Q1 FY2027  Group: Total 72 beds added during the quarter; 51 beds added in Noida while Lucknow witnessed 21 bed additions  On-boarded 70+ doctors including 50+ senior clinicians across the Medanta network to further strengthen clinical capabilities and patient care deliver  Guwahati Project: With the new Guwahati bye-laws and National Building Construction Standards (NBCS) 2026, built up area available for the hospital has increased. Accordingly, our scaled up plan is to have a 650 bedded super specialty hospital at a total capex of INR 9,700 million. Press Release GLOBAL HEALTH LIMITED 30th July, 2026 Financial Highlights: Q1 FY2027 Quarter INR million Q1FY2026 Q4FY2026 Q1FY2027 Y-o-Y Growth Revenue from operations 10,308 11,590 13,041 26.5% Other income 205 367 222 8.3% Total income 10,513 11,958 13,262 26.2% Cost of materials consumed 2,391 2,465 2,944 23.1% Employee benefits expense 3,852 4,615 5,136 33.3% Other expenses 1,717 1,971 2,029 18.2% EBITDA 2,553 2,906 3,153 23.5% EBITDA Margins % 24.3% 24.3% 23.8% (51) bps ESOP Expenses 79 101 64 (18.8)% EBITDA after ESOP expenses 2,474 2,805 3,089 24.8% Finance costs 138 267 267 93.5% Depreciation and amortisation 451 665 690 52.9% expense Exceptional item* (196) 0 0 na Profit before tax 2,081 1,873 2,133 2.5% Tax expenses 492 456 560 13.9% Profit after tax 1,590 1,417 1,573 (1.1)% *Q1FY26 had a non-recurring exceptional income of INR 196 million primarily due to reversal of potential interest liability on EPCG following transfer of EPCG license from MHPL to GHL ***** Press Release GLOBAL HEALTH LIMITED 30th July, 2026 About Global Health Limited (Medanta) Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth- highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine. Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited. Under the “Medanta” brand, the Company has a network of six hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,737 installed beds as on June 30, 2026. It also has five upcoming hospitals in Mumbai, Delhi (Pitampura [Showing first 8,000 characters — download PDF for full document]